Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cencora, Inc. stock logo
COR
Cencora
$223.95
-0.4%
$238.31
$163.37
$246.75
$44.67B0.471.29 million shs2.22 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$128.37
+1.4%
$132.11
$74.75
$142.00
$51.05B1.232.99 million shs1.78 million shs
Express Scripts Holding stock logo
ESRX
Express Scripts
$92.33
$92.33
$66.93
$101.73
$52.06B0.886.64 million shs31.61 million shs
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$85.25
+0.2%
$90.08
$60.57
$96.12
$51.37B1.13.00 million shs2.33 million shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cencora, Inc. stock logo
COR
Cencora
-0.33%-7.01%-8.86%-4.68%+34.22%
DexCom, Inc. stock logo
DXCM
DexCom
+1.36%+3.24%-7.32%+6.13%+9.42%
Express Scripts Holding stock logo
ESRX
Express Scripts
0.00%0.00%0.00%0.00%0.00%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
+0.21%-1.38%-8.36%-0.99%-3.25%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cencora, Inc. stock logo
COR
Cencora
4.4647 of 5 stars
2.42.01.73.13.03.32.5
DexCom, Inc. stock logo
DXCM
DexCom
4.9633 of 5 stars
3.55.00.04.72.62.53.1
Express Scripts Holding stock logo
ESRX
Express Scripts
N/AN/AN/AN/AN/AN/AN/AN/A
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
4.5687 of 5 stars
2.35.00.04.02.72.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cencora, Inc. stock logo
COR
Cencora
2.70
Moderate Buy$233.904.44% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.6710.36% Upside
Express Scripts Holding stock logo
ESRX
Express Scripts
N/AN/AN/AN/A
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
2.53
Moderate Buy$92.718.76% Upside

Current Analyst Ratings

Latest ESRX, EW, DXCM, and COR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/2/2024
Cencora, Inc. stock logo
COR
Cencora
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$275.00 ➝ $277.00
4/30/2024
Cencora, Inc. stock logo
COR
Cencora
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$265.00 ➝ $280.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$151.00 ➝ $160.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$144.00 ➝ $145.00
4/26/2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$94.00 ➝ $99.00
4/26/2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$92.00 ➝ $89.00
4/26/2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$83.00 ➝ $85.00
4/26/2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $88.00
4/15/2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$95.00 ➝ $101.00
4/11/2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$95.00 ➝ $105.00
4/10/2024
DexCom, Inc. stock logo
DXCM
DexCom
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$153.00 ➝ $163.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cencora, Inc. stock logo
COR
Cencora
$262.17B0.17$17.03 per share13.15$6.15 per share36.41
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B14.09$2.10 per share61.21$5.65 per share22.72
Express Scripts Holding stock logo
ESRX
Express Scripts
$100.06B0.52$10.49 per share8.80$32.00 per share2.89
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$6.00B8.56$2.77 per share30.78$11.93 per share7.15

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cencora, Inc. stock logo
COR
Cencora
$1.75B$9.1424.5015.211.690.67%268.67%4.13%8/7/2024 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.5582.8257.312.1616.82%31.01%10.29%7/25/2024 (Estimated)
Express Scripts Holding stock logo
ESRX
Express Scripts
$4.52B$7.1013.009.721.164.83%25.43%8.94%N/A
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$1.40B$2.3236.7527.413.5823.01%22.86%16.52%7/24/2024 (Estimated)

Latest ESRX, EW, DXCM, and COR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q2 2024
Cencora, Inc. stock logo
COR
Cencora
$3.65$3.80+$0.15$5.51$70.60 billion$68.41 billion    
4/25/2024Q1 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.27$0.32+$0.05$0.28$911.20 million$921.00 million    
4/25/2024Q1 2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$0.64$0.66+$0.02$0.74$1.58 billion$1.60 billion    
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      
2/6/2024Q4 23
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$0.64$0.64N/A$0.67$1.50 billion$1.53 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cencora, Inc. stock logo
COR
Cencora
$2.040.91%+4.95%22.32%1 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Express Scripts Holding stock logo
ESRX
Express Scripts
N/AN/AN/AN/AN/A
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
N/AN/AN/AN/AN/A

Latest ESRX, EW, DXCM, and COR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2024
Cencora, Inc. stock logo
COR
Cencora
quarterly$0.510.9%5/9/20245/10/20245/24/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cencora, Inc. stock logo
COR
Cencora
3.41
0.89
0.52
DexCom, Inc. stock logo
DXCM
DexCom
1.08
2.90
2.53
Express Scripts Holding stock logo
ESRX
Express Scripts
0.63
0.77
0.65
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
0.08
3.75
2.67

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cencora, Inc. stock logo
COR
Cencora
97.52%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Express Scripts Holding stock logo
ESRX
Express Scripts
84.87%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
79.46%

Insider Ownership

CompanyInsider Ownership
Cencora, Inc. stock logo
COR
Cencora
15.80%
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
Express Scripts Holding stock logo
ESRX
Express Scripts
0.79%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
1.29%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cencora, Inc. stock logo
COR
Cencora
46,000199.48 million167.96 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600397.68 million396.05 millionOptionable
Express Scripts Holding stock logo
ESRX
Express Scripts
N/A563.86 millionN/AOptionable
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
19,800602.60 million594.83 millionOptionable

ESRX, EW, DXCM, and COR Headlines

SourceHeadline
Amalgamated Bank Sells 10,327 Shares of Edwards Lifesciences Co. (NYSE:EW)Amalgamated Bank Sells 10,327 Shares of Edwards Lifesciences Co. (NYSE:EW)
marketbeat.com - May 4 at 10:46 AM
Michael A. Mussallem Sells 29,350 Shares of Edwards Lifesciences Co. (NYSE:EW) StockMichael A. Mussallem Sells 29,350 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock
americanbankingnews.com - May 4 at 4:10 AM
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from AnalystsEdwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - May 4 at 2:20 AM
Fisher Asset Management LLC Lowers Position in Edwards Lifesciences Co. (NYSE:EW)Fisher Asset Management LLC Lowers Position in Edwards Lifesciences Co. (NYSE:EW)
marketbeat.com - May 3 at 6:11 PM
Edwards Lifesciences Co. (NYSE:EW) Director Sells $2,487,999.50 in StockEdwards Lifesciences Co. (NYSE:EW) Director Sells $2,487,999.50 in Stock
insidertrades.com - May 3 at 6:42 AM
Jean-Luc M. Lemercier Sells 14,400 Shares of Edwards Lifesciences Co. (NYSE:EW) StockJean-Luc M. Lemercier Sells 14,400 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock
americanbankingnews.com - May 3 at 4:30 AM
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $11.59 Million Stake in Edwards Lifesciences Co. (NYSE:EW)Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $11.59 Million Stake in Edwards Lifesciences Co. (NYSE:EW)
marketbeat.com - May 2 at 10:01 PM
Insider Selling: Edwards Lifesciences Co. (NYSE:EW) Director Sells 29,350 Shares of StockInsider Selling: Edwards Lifesciences Co. (NYSE:EW) Director Sells 29,350 Shares of Stock
marketbeat.com - May 2 at 7:06 PM
Edwards Lifesciences Co. (NYSE:EW) VP Sells $1,212,624.00 in StockEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,212,624.00 in Stock
insidertrades.com - May 2 at 6:16 AM
Raymond James Financial Services Advisors Inc. Has $109.38 Million Stake in Edwards Lifesciences Co. (NYSE:EW)Raymond James Financial Services Advisors Inc. Has $109.38 Million Stake in Edwards Lifesciences Co. (NYSE:EW)
marketbeat.com - May 1 at 11:06 PM
Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 14,400 Shares of StockInsider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 14,400 Shares of Stock
marketbeat.com - May 1 at 7:45 PM
Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?
zacks.com - May 1 at 10:46 AM
Down -10.22% in 4 Weeks, Heres Why You Should You Buy the Dip in Edwards Lifesciences (EW)Down -10.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Edwards Lifesciences (EW)
zacks.com - May 1 at 10:35 AM
Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 7,250 SharesEdwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 7,250 Shares
insidertrades.com - May 1 at 4:44 AM
Edwards Isn’t Sweating the SMART ResultsEdwards Isn’t Sweating the SMART Results
mddionline.com - May 1 at 1:07 AM
Scott B. Ullem Sells 7,250 Shares of Edwards Lifesciences Co. (NYSE:EW) StockScott B. Ullem Sells 7,250 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock
marketbeat.com - April 30 at 7:10 PM
Edwards Lifesciences Corporation (NYSE:EW) Q1 2024 Earnings Call TranscriptEdwards Lifesciences Corporation (NYSE:EW) Q1 2024 Earnings Call Transcript
finance.yahoo.com - April 30 at 1:20 PM
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
zacks.com - April 30 at 9:56 AM
Hold Rating Justified for Edwards Lifesciences Amid TAVR Segment UncertaintiesHold Rating Justified for Edwards Lifesciences Amid TAVR Segment Uncertainties
markets.businessinsider.com - April 30 at 8:19 AM
Edwards Lifesciences (NYSE:EW) Upgraded by StockNews.com to "Buy"Edwards Lifesciences (NYSE:EW) Upgraded by StockNews.com to "Buy"
americanbankingnews.com - April 30 at 6:28 AM
Invera Wealth Advisors LLC Has $2.97 Million Position in Edwards Lifesciences Co. (NYSE:EW)Invera Wealth Advisors LLC Has $2.97 Million Position in Edwards Lifesciences Co. (NYSE:EW)
marketbeat.com - April 30 at 12:29 AM
StockNews.com Upgrades Edwards Lifesciences (NYSE:EW) to BuyStockNews.com Upgrades Edwards Lifesciences (NYSE:EW) to Buy
marketbeat.com - April 29 at 11:19 PM
Investing in Edwards Lifesciences (EW)? Dont Miss Assessing Its International Revenue TrendsInvesting in Edwards Lifesciences (EW)? Don't Miss Assessing Its International Revenue Trends
zacks.com - April 29 at 1:20 PM
Evercore ISI Cuts Edwards Lifesciences (NYSE:EW) Price Target to $89.00Evercore ISI Cuts Edwards Lifesciences (NYSE:EW) Price Target to $89.00
americanbankingnews.com - April 29 at 6:08 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Cencora logo

Cencora

NYSE:COR
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Express Scripts logo

Express Scripts

NASDAQ:ESRX
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Edwards Lifesciences logo

Edwards Lifesciences

NYSE:EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.